A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
Clinical trial NCT05893862 · COMPLETED
Trial details
- NCT number
- NCT05893862
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-26
- Primary completion
- 2024-02-22
- Enrollment
- 107
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.